 Toxicity high-dose cytosine arabinoside treatment advanced childhood tumors conventional therapy Pediatric Oncology Group study Experience high-dose cytosine arabinoside HDAC pediatric solid tumors limited Sixteen children solid tumors conventional therapies pilot Pediatric Oncology Group POG study administration HDAC hours doses cases rhabdomyosarcoma cases fibrosarcoma cases neuroblastoma case germ cell tumor Wilm tumor retinoblastoma hepatocellular carcinoma Ewing sarcoma Burkitt lymphoma eligible patients diseases extensive chemotherapy Thirteen patients course HDAC patients courses HDAC Due treatments patients normal marrow reserves Short-term toxicity nausea suppression hemopoiesis drug fever blood urea nitrogen BUN creatinine enzymes evaluable patients toxicities drug-related deaths None patients neurologic problems patient prior irradiation skull schedule HDAC manageable toxicity